| 1 |
Kim HO, Cho CH, Cho YJ, et al. Significant associations of PAI-1 genetic polymorphisms with osteonecrosis of the femoral head [J]. BMC Musculoskelet Disord, 2011, 12 :160-160.
|
| 2 |
Yin J M, Liu Z, Zhao S C, et al. Relationship between the Apolipoprotein AI, B gene polymorphism and the risk of non-traumatic osteonecrosis[J]. Lipids in Health and Disease, 2014, 13(1):149.
|
| 3 |
Juhan-Vague J, I. Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis [J]. Thromb Haemost, 1987, 57(1): 67-72.
|
| 4 |
Liguori, R. A novel polymorphism in the PAI-1 gene promoter enhances gene expression. A novel pro-thrombotic risk factor? [J]. Thromb Res, 2014, 134(6): 1229-1233.
|
| 5 |
Brogren H, Karlsson L, Andersson M, et al. Platelets synthesize large amounts of active plasminogen activator inhibitor 1 [J]. Blood, 2004, 104(13): 3943-3948.
|
| 6 |
Al-Horani RA. Serpin regulation of fibrinolytic system: implications for therapeutic applications in cardiovascular diseases [J]. Cardiovasc Hematol Agents Med Chem, 2014, 12(2): 91-125.
|
| 7 |
Chapman MP, Moore EE, Moore HB, et al. Overwhelming tPA release, not PAI-1 degradation, is responsible for hyperfibrinolysis in severely injured trauma patients [J]. J Trauma Acute Care Surg, 2016, 80(1): 16-25.
|
| 8 |
Dawson S, Hamsten A, Wiman B, et al. Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity [J]. Arterioscler Thromb, 1991, 11(1): 183-190.
|
| 9 |
Eriksson P, Kallin B, Vanthooft FM, et al. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction [J]. Proc Natl Acad Sci USA, 1995, 92(6): 1851-1855.
|
| 10 |
Li Y, Liu FX, Yuan C, et al. Association between plasminogen activator inhibitor gene polymorphisms and osteonecrosis of the femoral head susceptibility: A case-control study [J]. Medicine (Baltimore), 2017, 96(42): e7047.
|
| 11 |
Kerachian MA, Séguin C, Harvey EJ. Glucocorticoids in osteonecrosis of the femoral head: a new understanding of the mechanisms of action [J]. J Steroid Biochem Mol Biol, 2009, 114(3/5): 121-128.
|
| 12 |
Gong LL, Fang LH, Wang HY, et al. Genetic risk factors for glucocorticoid-induced osteonecrosis: a meta-analysis [J]. Steroids, 2013, 78(4): 401-408.
|
| 13 |
Hosseini, S. Genetic risk factors in patients with deep venous thrombosis,a retrospective case control study on Iranian population [J]. Thromb J, 2015, 13 :35.
|
| 14 |
Girard TJ, Warren LA, Novotny WF, et al. Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor [J]. Nature, 1989, 338(6215): 518-520.
|
| 15 |
Lindahl AK. Tissue factor pathway inhibitor: from unknown coagulation inhibitor to major antithrombotic principle [J]. Cardiovasc Res, 1997, 33(2): 286-291.
|
| 16 |
Rapaport SI, Rao LV. The tissue factor pathway: how it has become a "prima ballerina" [J]. Thromb Haemost, 1995, 74(1): 7-17.
|
| 17 |
Amini-Nekoo A, Futers TS, Moia M, et al. Analysis of the tissue factor pathway inhibitor gene and antigen levels in relation to venous thrombosis [J]. Br J Haematol, 2001, 113(2): 537-543.
|
| 18 |
He MX, Wen ZB, He XF, et al. Observation on tissue factor pathway and some other coagulation parameters during the onset of acute cerebrocardiac thrombotic diseases [J]. Thromb Res, 2002, 107(5): 223-228.
|
| 19 |
Ameziane N, Seguin C, Borgel D, et al. The-33T -> C polymorphism in intron 7 of the TFPI gene influences the risk of venous thromboembolism, independently of the factor V Leiden and prothrombin mutations [J]. Thromb Haemost, 2002, 88(2): 195-199.
|
| 20 |
Moatti D, Seknadji P, Galand C, et al. Polymorphisms of the tissue factor pathway inhibitor (TFPI) gene in patients with acute coronary syndromes and in healthy subjects - Impact of the V264M substitution on plasma levels of TFPI [J]. Arterioscler Thromb Vasc Biol, 1999, 19(4): 862-869.
|
| 21 |
Moatti, D. A new T-287C polymorphism in the 5'regulatory region of the tissue factor pathway inhibitor gene Association study of the T-287C and C-399T polymorphisms with coronary artery disease and plasma TFPI levels [J]. Thromb Haemost, 2000, 84(2): 244-249.
|
| 22 |
Dai XL, Hong JM, Oh B, et al. Association analysis of tissue factor pathway inhibitor polymorphisms and haplotypes with osteonecrosis of the femoral head in the korean population [J]. Mol Cells, 2008, 26(5): 490-495.
|
| 23 |
Heijer D, M. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis [J]. N Engl J Med, 1996, 334(12): 759-762.
|
| 24 |
Zalavras CG, Malizos KN, Dokou E, et al. The 677C -> T mutation of the methylene-tetra-hydrofolate reductase gene in the pathogenesis of osteonecrosis of the femoral head [J]. Haematologica, 2002, 87(1): 111-112.
|
| 25 |
Chang JD, Hur M, Lee SS, et al. Genetic background of nontraumatic osteonecrosis of the femoral head in the Korean population [J]. Clin Orthop Relat Res, 2008, 466(5): 1041-1046.
|
| 26 |
Asano T, Takahashi KA, Fujioka M, et al. Relationship between postrenal transplant osteonecrosis of the femoral head and gene polymorphisms related to the coagulation and fibrinolytic systems in Japanese subjects [J]. Transplantation, 2004, 77(2): 220-225.
|
| 27 |
Primo-Parmo SL, Sorenson RC, Teiber J, et al. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family [J]. Genomics, 1996, 33(3): 498-507.
|
| 28 |
Mackness M, Mackness B. Human paraoxonase-1 (PON1): Gene structure and expression, promiscuous activities and multiple physiological roles [J]. Gene, 2015, 567(1): 12-21.
|
| 29 |
Deakin S, Leviev I, Gomaraschi M, et al. Enzymatically active paraoxonase-1 is located at the external membrane of producing cells and released by a high affinity, saturable, desorption mechanism [J]. J Biol Chem, 2002, 277(6): 4301-4308.
|
| 30 |
Pera-Kajan J, Jakubowski H. Paraoxonase 1 and homocysteine metabolism [J]. Amino Acids, 2012, 43(4): 1405-1417.
|
| 31 |
Shih DM, Lusis AJ. The roles of PON1 and PON2 in cardiovascular disease and innate immunity [J]. Curr Opin Lipidol, 2009, 20(4): 288-292.
|
| 32 |
Fridman O, Fuchs AG, Porcile R, et al. [Paraoxonase: its multiple functions and pharmacological regulation]. Arch Cardiol Mex, 2011, 81(3): 251-260.
|
| 33 |
Cui Y, Kaisaierjiang A, Cao P, et al. Association of apolipoprotein A5 genetic polymorphisms with steroid-induced osteonecrosis of femoral head in a Chinese Han population [J]. Diagn Pathol, 2014, 9(1): 229-229.
|
| 34 |
Miyanishi K, Yamamoto T, Irisa T, et al. Increased level of apolipoprotein B/apolipoprotein A1 ratio as a potential risk for osteonecrosis [J]. Ann Rheum Dis, 1999, 58(8): 514-516.
|
| 35 |
Schmidt R, Schmidt H, Fazekas F, et al. MRI cerebral white matter lesions and paraoxonase PON1 polymorphisms - Three-year follow-up of the Austrian stroke prevention study [J]. Arterioscler Thromb Vasc Biol, 2000, 20(7): 1811-1816.
|
| 36 |
Hadjigeorgiou GM, Malizos K, Dardiotis E, et al. Paraoxonase 1 gene polymorphisms in patients with osteonecrosis of the femoral head with and without cerebral white matter lesions [J]. J Orthop Res, 2007, 25(8): 1087-1093.
|
| 37 |
Wang Z, Zhang Y, Kong X, et al. Association of a polymorphism in PON-1 gene with steroid-induced osteonecrosis of femoral head in Chinese Han population [J]. Diagn Pathol, 2013, 8 :186.
|
| 38 |
Li JM, Li Y, Wang L. The genetic association between PON1 polymorphisms and osteonecrosis of femoral head: A case-control study [J]. Medicine (Baltimore), 2017, 96(42): e8198.
|
| 39 |
Wang XD, Sato R, Brown MS, et al. SREBP-1, a membrane-bound transcription factor released by sterol-regulated proteolysis [J]. Cell, 1994, 77(1): 53-62.
|
| 40 |
Kolehmainen M, Vidal H, Alhava E, et al. Sterol regulatory element binding protein 1c (SREBP-1c) expression in human obesity [J]. Obes Res, 2001, 9(11): 706-712.
|
| 41 |
Oberkofler H, Fukushima N, Esterbauer H, et al. Sterol regulatory element binding proteins: relationship of adipose tissue gene expression with obesity in humans [J]. Biochim Biophys Acta, 2002, 1575(1/3): 75-81.
|
| 42 |
You M, Crabb DW. Molecular mechanisms of alcoholic fatty liver: role of sterol regulatory element-binding proteins [J]. Alcohol, 2004, 34(1): 39-43.
|
| 43 |
Lee HJ, Choi SJ, Hong JM, et al. Association of a polymorphism in the intron 7 of the SREBF1 gene with osteonecrosis of the femoral head in koreans [J]. Ann Hum Genet, 2009, 73(1): 34-41.
|
| 44 |
Wang YS, Li YB, Mao KY, et al. Alcohol-induced adipogenesis in bone and marrow: A possible mechanism for osteonecrosis [J]. Clin Orthop Relat Res, 2003, 410(410): 213-224.
|
| 45 |
Olszewski MB, Groot AJ, Dastych J, et al. TNF trafficking to human mast cell granules: Mature chain-dependent endocytosis [J]. J Immunol, 2007, 178(9): 5701-5709.
|
| 46 |
Hayashi K, Piras V, Tabata S, et al. A systems biology approach to suppress TNF-induced proinflammatory gene expressions [J]. Cell Commun Signal, 2013, 11(1): 1-15.
|
| 47 |
Shibahara M, Nishida K, Asahara H, et al. Increased osteocyte apoptosis during the development of femoral head osteonecrosis in spontaneously hypertensive rats [J]. Acta Med Okayama, 2000, 54(2): 67-74.
|
| 48 |
Dai CY, Chuang WL, Lee LP, et al. Associations of tumour necrosis factor alpha promoter polymorphisms at position-308 and -238 with clinical characteristics of chronic hepatitis C [J]. J Viral Hepat, 2006, 13(11): 770-774.
|
| 49 |
Scheper MA, Badros A, Chaisuparat R, et al. Effect of zoledronic acid on oral fibroblasts and epithelial cells: a potential mechanism of bisphosphonate-associated osteonecrosis [J]. Br J Haematol, 2009, 144(5): 667-676.
|
| 50 |
Okazaki S, Nishitani Y, Nagoya S, et al. Femoral head osteonecrosis can be caused by disruption of the systemic immune response via the toll-like receptor 4 signalling pathway [J]. Rheumatology (Oxford), 2009, 48(3): 227-232.
|
| 51 |
Wu X, Feng X, He Y, et al. IL-4 administration exerts preventive effects via suppression of underlying inflammation and TNF-α-induced apoptosis in steroid-induced osteonecrosis [J]. Osteoporos Int, 2016, 27(5): 1-11.
|
| 52 |
Zhang BB, Liu XZ, Sun J, et al. Association between TNF α gene polymorphisms and the risk of duodenal ulcer: a meta-analysis [J]. PLoS One, 2013, 8(2): e57167.
|
| 53 |
Samara S, Kollia P, Dailiana Z, et al. Predictive role of cytokine gene polymorphisms for the development of femoral head osteonecrosis [J]. Dis Markers, 2012, 33(4): 215-221.
|
| 54 |
Sghaier I, Zidi S, Mouelhi L, et al. The relationship between TNF alpha gene polymorphisms (-238/-308), TNF RII VNTR (p75) and outcomes of hepatitis B virus infection in Tunisian population [J]. Gene, 2015, 568(2): 140-145.
|
| 55 |
Peng YZ, Liu YE, Huang DH, et al. Association of TNF-alpha-308(G/A) and-238(G/A) polymorphisms with non-traumatic osteonecrosis of the femoral head risks: a meta-analysis [J]. Int Orthop, 2018, 42(7, SI): 1711-1721.
|
| 56 |
Tyrovola, J B. Root resorption and the OPG/RANKL/RANK system: a mini review [J]. J Oral Sci, 2008, 50(4): 367-376.
|
| 57 |
Wada T, Nakashima T, Hiroshi N, et al. RANKL-RANK signaling in osteoclastogenesis and bone disease [J]. Trends Mol Med, 2006, 12(1): 17-25.
|
| 58 |
Hofbauer LC. Pathophysiology of RANK ligand (RANKL) and osteoprotegerin (OPG) [J]. Ann Endocrinol (Paris), 2006. 67(2): 139-41.
|
| 59 |
Boyce BF, Xing L. The RANKL/RANK/OPG pathway [J]. Curr Osteoporos Rep, 2007. 5(3): 98-104.
|
| 60 |
Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling [J]. Arch Biochem Biophys, 2008, 473(2): 139-146.
|
| 61 |
Li YZ, Wang Y, Guo YC, et al. OPG and RANKL polymorphisms are associated with alcohol-induced osteonecrosis of the femoral head in the North area of China population in men [J]. Medicine (Baltimore), 2016, 95(25): e3981-e3981.
|
| 62 |
Li YZ, Guo YC, Wang QJ, et al. Osteoprotegerin polymorphisms are associated with alcohol-induced osteonecrosis of femoral head in Chinese Han population from Henan province [J]. J Genet, 2016, 95(4): 983-989.
|
| 63 |
Karsdal MA1, Andersen TA, Bonewald L, et al. Safeguard osteoblasts from apoptosis during transdifferentiation into osteocytes: MT1-MMP maintains osteocyte viability [J]. DNA Cell Biol, 2004, 23(3): 155-165.
|
| 64 |
Nakai K, Kawato T, Morita T, et al. Angiotensin II induces the production of MMP-3 and MMP-13 through the MAPK signaling pathways via the AT(1) receptor in osteoblasts [J]. Biochimie, 2013, 95(4): 922-933.
|
| 65 |
Mosig RA, Dowling O, Difeo A, et al. Loss of MMP-2 disrupts skeletal and craniofacial development and results in decreased bone mineralization, joint erosion and defects in osteoblast and osteoclast growth [J]. Hum Mol Genet, 2007, 16(9): 1113-1123.
|
| 66 |
Shi J, Son MY, Yamada S, et al. Membrane-type MMPs enable extracellular matrix permissiveness and mesenchymal cell proliferation during embryogenesis [J]. Dev Biol, 2008, 313(1): 196-209.
|
| 67 |
Ota I, Li XY, Hu YE, et al. Induction of a MT1-MMP and MT2-MMP-dependent basement membrane transmigration program in cancer cells by Snail1 [J]. Proc Natl Acad Sci U S A, 2009, 106(48): 20318-20323.
|
| 68 |
Radisky ES, Radisky DC. Matrix Metalloproteinase-Induced Epithelial-Mesenchymal transition in breast cancer [J]. J Mammary Gland Biol Neoplasia, 2010, 15(2): 201-212.
|
| 69 |
Vidal NO, Brandstrom H, Jonsson KB, et al. Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: down-regulation by glucocorticoids [J]. J Endocrinol, 1998, 159(1): 191-195.
|
| 70 |
Geoffroy V, Marty-Morieux C, Le Goupil N, et al. In vivo inhibition of osteoblastic metalloproteinases leads to increased trabecular bone mass [J]. J Bone Miner Res, 2004, 19(5): 811-822.
|
| 71 |
Bord S, Horner A, Beeton CA, et al. Tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) distribution in normal and pathological human bone [J]. Bone, 1999, 24(3): 229-235.
|
| 72 |
Du JL, Jin TB, Cao YJ, et al. Association between genetic polymorphisms of MMP8 and the risk of steroid-induced osteonecrosis of the femoral head in the population of northern China [J]. Medicine, 2016, 95(37): e4794-e4794.
|
| 73 |
Du J, Liu W, Jin T, et al. A single-nucleotide polymorphism in MMP9 is associated with decreased risk of steroid-induced osteonecrosis of the femoral head [J]. Oncotarget, 2016, 7(42): 68434-68441.
|
| 74 |
Chen JY, Liu WL, Cao YJ, et al. MMP-3 and MMP-8 single-nucleotide polymorphisms are related to alcohol-induced osteonecrosis of the femoral head in Chinese males [J]. Oncotarget, 2017, 8(15): 25177-25188.
|
| 75 |
Koo KH, Lee JS, Lee YJ, et al. Endothelial nitric oxide synthase gene polymorphisms in patients with nontraumatic femoral head osteonecrosis [J]. J Orthop Res, 2006, 24(8): 1722-1728.
|
| 76 |
Gagala J, Buraczynska M, Tomasz Mazurkiewicz. Endothelial nitric oxide synthase gene intron 4 polymorphism in non-traumatic osteonecrosis of the femoral head[J]. International Orthopaedics, 2013, 37(7):1381-1385.
|
| 77 |
Zhen Xiao, Corinne E Camalier, Kunio Nagashima, et al.. Analysis of the Extracellular Matric Vesicle Proteiome in mineralizing osteoblasts [J]. Journal of Cellular Physiology, 2007, 210(2):325-335.
|
| 78 |
Kim T H, Hong J M, Shin E S, et al. Polymorphisms in the Annexin gene family and the risk of osteonecrosis of the femoral head in the Korean population[J]. Bone, 2009, 45(1):0-131.
|
| 79 |
Wang J, Liu H, Zhang Q. IGF-1 polymorphisms modulate the susceptibility to osteonecrosis of the femoral head among Chinese Han population[J]. Medicine, 2019, 98.
|